- Home
- BSLK vs EDSA Comparison
BSLK vs EDSA Comparison
Compare BSLK & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSLK
- EDSA
- Stock Information
- Founded
- BSLK 2009
- EDSA 2015
- Country
- BSLK United States
- EDSA Canada
- Employees
- BSLK N/A
- EDSA N/A
- Industry
- BSLK
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- BSLK
- EDSA Health Care
- Exchange
- BSLK NYSE
- EDSA Nasdaq
- Market Cap
- BSLK 12.3M
- EDSA 14.7M
- IPO Year
- BSLK N/A
- EDSA N/A
- Fundamental
- Price
- BSLK $3.00
- EDSA $2.39
- Analyst Decision
- BSLK
- EDSA Strong Buy
- Analyst Count
- BSLK 0
- EDSA 2
- Target Price
- BSLK N/A
- EDSA $13.00
- AVG Volume (30 Days)
- BSLK 5.5M
- EDSA 31.0K
- Earning Date
- BSLK 08-21-2025
- EDSA 08-08-2025
- Dividend Yield
- BSLK N/A
- EDSA N/A
- EPS Growth
- BSLK N/A
- EDSA N/A
- EPS
- BSLK N/A
- EDSA N/A
- Revenue
- BSLK $1,525,000.00
- EDSA N/A
- Revenue This Year
- BSLK N/A
- EDSA N/A
- Revenue Next Year
- BSLK N/A
- EDSA N/A
- P/E Ratio
- BSLK N/A
- EDSA N/A
- Revenue Growth
- BSLK N/A
- EDSA N/A
- 52 Week Low
- BSLK $1.75
- EDSA $1.55
- 52 Week High
- BSLK $340.40
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- BSLK N/A
- EDSA 73.15
- Support Level
- BSLK N/A
- EDSA $1.89
- Resistance Level
- BSLK N/A
- EDSA $2.23
- Average True Range (ATR)
- BSLK 0.00
- EDSA 0.11
- MACD
- BSLK 0.00
- EDSA 0.04
- Stochastic Oscillator
- BSLK 0.00
- EDSA 81.54
About BSLK BOLT PROJECTS HOLDINGS INC
Bolt Projects Holdings Inc develops and produces biomaterials products. Its flagship products from its Vegan Silk Technology Platform, b-silk and xl-silk, are a biodegradable and vegan protein polymer and a replacement for silicone elastomers in beauty and personal care.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.